Clinical study of detorubicin. EORTC Clinical Screening Group

A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of the breast carcinoma patients, in 17% of the head and neck carcinoma patients and melanoma patients, and in 6% of the uteri cervix carcinoma patients. DTR seems to be as toxic as adriamycin for bone marrow and heart, but might induce a little less alopecia.